We’re proud to share that our LIVERFASt® performance study has been officially published, marking an important milestone in the non-invasive […]
Fibronostics is excited to announce our participation in the MASH-TAG 2026 Conference, held from January 8-10, 2026, in beautiful Deer
At Fibronostics, our mission is built on a foundation of precision and trust. We are proud to announce that we
Fibronostics is thrilled to announce its participation in the AASLD Liver Meeting 2025, the world’s leading conference dedicated to advancing
We’re excited to announce that Fibronostics has completed the acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced
On June 11-13, Fibronostics had the privilege of participating in the THASL 2025 Annual Conference, hosted by the Thai Association
In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4
Fibronostics is pleased to announce its participation in the THASL 2025 Annual Conference, hosted by the Thai Association for the Study of the
Fibronostics is now officially SOC 2 Type II compliant! This compliance reflects our deep commitment to keeping your data and
We did it again! Fibronostics is proud to announce that we have successfully renewed our ISO 27001:2022 certification for